Guangze Li
5 Papers
4 Citations
Guangze Li is an academic researcher. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Tomato based gelatin methacryloyl hydrogel as an effective natural and low-cost scaffold for accelerative wound healing.
TL;DR: In this paper , a novel type of tissue engineering scaffold, based on tomatoes (Solanum lycopersicon) and gelatin methacryloyl (GelMA), was prepared via facile lyophilization and photo cross-link method.
24
Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Jianming Xu,Rongrui Liu,Yi Ba,Da Jiang,Mingxia Wang,Yulong Zheng,Jia Wei,Yuxian Bai,Lizhu Lin,Jianping Xiong,Xixi Zhu,Chuanhua Zhao,Ru Jia,Yun Zhang,Jianzhi Liu,Gairong Zhang,Guangze Li,Quanren Wang +17 more
TL;DR: In a gastric cancer PDX model, fluzoparib + apatinib + paclitaxel demonstrated significant tumor growth inhibition as well as selective PARP1 inhibition in a double-blind, placebo-controlled study.
5
A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
Hua Zhang,Shu Yan,Yan Zhan,Shengyao Ma,Yicong Bian,Shaorong Li,J Tian,Guangze Li,Dafang Zhong,Xingxing Diao,Liyan Miao +10 more
TL;DR: Wang et al. as mentioned in this paper investigated the metabolism, mass balance, and pharmacokinetics of SHR6390 in 6 healthy Chinese male subjects after a single oral dose of 150 mg.
3
Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers
Yicong Bian,Jian Meng,Shengyao Ma,Guangze Li,Yu-Ying Wang,Shaorong Li,Linsheng Liu,Chenrong Huang,Hua Zhang,Dafang Zhong,Liyan Miao +10 more
TL;DR: This trial investigated the metabolite profiles, mass balance and pharmacokinetics of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers.
3
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
Huiping Li,Rongrui Liu,Bin Shao,Ran Ran,Guohong Song,Ke Wang,Yehui Shi,Jihong Liu,Wen Jing Hu,Fu Chen,Xiaoran Liu,Gairong Zhang,Chuanhua Zhao,Ru Jia,Quanren Wang,Hope S. Rugo,Yifan Zhang,Guangze Li,Jianming Xu +18 more
TL;DR: Fluzoparib demonstrated single-agent antitumor activity in BC and OC, particularly in BRCAMut and platinum-sensitive OC, and in patients with germline BC susceptibility gene mutation.